Related Experiment Videos
Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic
E B Keeffe1, G M Dusheiko, M J Tong
1Stanford University Medical Center, Palo Alto, CA 94304-1509, USA. ekeeffe@stanford.edu
Insights
Hepatitis C virus (HCV) genotype 1 patients respond differently to interferon therapy. Nonresponders with genotype 1 showed slower HCV RNA decrease compared to genotypes 2 and 3.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis C virus (HCV) infection is a global health concern.
- Interferon-based therapies have been used to treat chronic hepatitis C.
- Lower response rates are observed in patients with HCV genotype 1.
Purpose of the Study:
- To investigate the pattern of HCV RNA decline during interferon treatment across different HCV genotypes.
- To determine if slower HCV clearance contributes to lower response rates in genotype 1 patients.
- To compare the efficacy of consensus interferon (CIFN) and interferon alfa-2b (IFN alfa-2b) in relation to HCV genotype.
Main Methods:
- Analysis of serum HCV RNA levels in 472 chronic hepatitis C patients.
- Patients were treated with either CIFN or IFN alfa-2b.
- Evaluation of HCV RNA decline patterns based on genotype and treatment response (sustained responders, relapsers, nonresponders).
Main Results:
- Sustained responders and relapsers showed similar HCV RNA decline patterns regardless of genotype.
- Nonresponders with genotype 1 exhibited a significantly slower HCV RNA decrease compared to genotypes 2 and 3.
- HCV genotype 1 patients receiving CIFN showed a greater HCV RNA decrease than those receiving IFN alfa-2b, but no difference was observed for genotypes 2 or 3.
Conclusions:
- HCV genotype and treatment outcome significantly influence the rate of HCV RNA decline during interferon therapy.
- Genotype 1 nonresponders demonstrate impaired viral kinetics compared to other genotypes.
- Consensus interferon may offer a more pronounced viral load reduction in genotype 1 patients.
Abstract:
We assessed differences in the pattern of HCV RNA decrease for HCV genotypes 1, 2, and 3 during interferon treatment to determine if the lower response rates observed among genotype 1 patients were related to a slower decrease in HCV clearance. Serum HCV RNA values of 472 chronic hepatitis C patients treated with either consensus interferon (CIFN) or interferon alfa-2b (IFN alfa-2b) were evaluated. Neither virological sustained responders nor relapsers differed in the pattern of serum HCV RNA decrease based on genotype. Virological sustained responders infected with genotype 1 cleared HCV RNA as rapidly as sustained responders who were infected with genotype 2 or 3. Relapsers had a slower rate of serum HCV RNA decrease than did virological sustained responders. Nonresponders differed in the pattern of serum HCV RNA decrease based on genotype: HCV genotype 3 patients had the greatest decrease in serum HCV RNA; genotype 2 patients had an intermediate decrease; and genotype 1 patients had the least serum HCV RNA decrease. HCV genotype 1 patients treated with CIFN had a greater decrease in serum HCV RNA during therapy than did patients treated with IFN alfa-2b. However, there was no difference in the magnitude of serum HCV RNA decrease between the two interferon treatments for patients infected with genotype 2 or 3. In summary, both genotype and ultimate response to treatment are determinants of the pattern and rate of serum HCV RNA change during interferon therapy of chronic hepatitis C.